Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients

PARP inhibitors (PARPi) have increased treatment options in ovarian cancer, particularly in patients with BRCA1/2 mutations, although there are still marked differences in the duration of patients’ response to this targeted therapy. BRCA testing is routinely performed in tumor tissue of ovarian canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Grech, Christina T., Pils, Dietmar, Aust, Stefanie, Grimm, Christoph, Polterauer, Stephan, Reinthaller, Alexander, Müllauer, Leonhard, Reischer, Theresa, Bekos, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504000/
https://www.ncbi.nlm.nih.gov/pubmed/36143252
http://dx.doi.org/10.3390/jpm12091467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504000/
https://www.ncbi.nlm.nih.gov/pubmed/36143252
http://dx.doi.org/10.3390/jpm12091467

Ejemplares similares